Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 9/20 | 0.68 |
| ▸ | F10 | P00742 | 9/20 | 0.68 |
| ▸ | F7 | P08709 | 3/20 | 0.68 |
| ▸ | PLAU | P00749 | 7/20 | 0.66 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.66 |
| ▸ | PLG | P00747 | 6/20 | 0.63 |
| ▸ | PLAT | P00750 | 5/20 | 0.63 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.61 |
| ▸ | HPN | P05981 | 1/20 | 0.61 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14259601 | 1.00 | F2 (0.68) | F2F10F7PLAUPRSS1 | |
| SCHEMBL12348382 | 0.93 | PLAU (0.62) | F2F10F7PLAUPRSS1 | |
| SCHEMBL13167152 | 0.92 | F2 (0.59) | F2F10F7PLAUPRSS1 | |
| SCHEMBL13167141 | 0.92 | PLAU (0.62) | F2F10F7PLAUPRSS1 | |
| SCHEMBL30689279 | 0.89 | F10 (0.61) | F2F10F7PLAUPRSS1 | |
| SCHEMBL14599572 | 0.89 | F10 (0.61) | F2F10F7PLAUPRSS1 | |
| SCHEMBL549166 | 0.88 | F2 (0.56) | F2F10F7PLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL11294147 | 0.87 | F2 (0.55) | F2F10F7PLAUPRSS1 | |
| SCHEMBL13882980 | 0.85 | PLAU (0.55) | F2F10F7PLAUPRSS1 | |
| SCHEMBL13167166 | 0.85 | PLAU (0.53) | F2F10F7PLAUPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101435-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2024247428-A1 | FOOD PROPOSAL DEVICE, FOOD PROPOSAL METHOD, AND PROGRAM | パナソニックＩＰマネジメント株式会社 | 2024-12-05 | — | — | WO | disclosed |
| WO-2024089820-A1 | INFORMATION DISTRIBUTION DEVICE, PREDICTION SYSTEM, INFORMATION DISTRIBUTION METHOD, AND PROGRAM | 日本電信電話株式会社 | 2024-05-02 | — | — | WO | disclosed |
| US-20240052354-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-02-15 | — | — | US | disclosed |
| WO-2023170803-A1 | DESIGN AUTOMATION DEVICE, DESIGN AUTOMATION SYSTEM, DESIGN AUTOMATION METHOD, AND DESIGN AUTOMATION PROGRAM | 三菱電機株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023058310-A1 | ARTICLE MANAGEMENT SYSTEM, METHOD AND READING DEVICE | キヤノン株式会社 | 2023-04-13 | — | — | WO | disclosed |
| WO-2023286425-A1 | DEVICE FOR ASSISTING WITH CHANGING OPERATION PLAN, METHOD FOR ASSISTING WITH CHANGING OPERATION PLAN, AND TRAIN OPERATION MANAGEMENT SYSTEM | 株式会社日立製作所 | 2023-01-19 | — | — | WO | disclosed |
| US-11530413-B2 | Compositions and methods to treat cancer | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| WO-2022234693-A1 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, AND PROGRAM | ソニーグループ株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4085919-A2 | COMPOSITIONS AND METHODS TO TREAT CANCER | Novartis AG (CH) | 2022-11-09 | — | — | EP | disclosed |
| CN-110317496-B | Aqueous inkjet composition | 精工爱普生株式会社 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022210352-A1 | ARTICLE MANAGEMENT SYSTEM, ARTICLE MANAGEMENT METHOD, READING DEVICE, AND INFORMATION PROCESSING DEVICE | キヤノン株式会社 | 2022-10-06 | — | — | WO | disclosed |
| US-11384249-B2 | Aqueous ink jet composition | SEIKO EPSON CORPORATION (JP) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240052354-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | TP53, BRCA1, NTPCR | F2 3780/4885F10 3393/4885F7 3326/4885 |
| US-11530413-B2 | Compositions and methods to treat cancer | TP53, BRCA1, NTPCR | F2 3780/4885F10 3393/4885F7 3326/4885 |
| US-20250101435-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | TP53, BRCA1, NTPCR | F2 3780/4885F10 3393/4885F7 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.